141 related articles for article (PubMed ID: 36545394)
1. Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy.
Liu Y; Yang S; Zhou Q; Zhou J; Li J; Ma Y; Hu B; Liu C; Zhao Y
Nanoscale Adv; 2022 Nov; 4(22):4847-4862. PubMed ID: 36545394
[TBL] [Abstract][Full Text] [Related]
2. Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect.
Huang X; Chen Y; Zhong F; Gui B; Hu Y; Guo Y; Deng Q; Zhou Q
Int J Nanomedicine; 2024; 19():2793-2806. PubMed ID: 38525011
[TBL] [Abstract][Full Text] [Related]
3. Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice.
Tan Y; Yang S; Ma Y; Li J; Xie Q; Liu C; Zhao Y
Int J Nanomedicine; 2021; 16():3241-3254. PubMed ID: 34007176
[TBL] [Abstract][Full Text] [Related]
4. Nanobubble-mediated co-delivery of Ce6 and miR-195 for synergized sonodynamic and checkpoint blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma.
Ma Y; Li J; Zhao Y; Hu B; Liu Y; Liu C
Eur J Pharm Biopharm; 2022 Dec; 181():36-48. PubMed ID: 36307001
[TBL] [Abstract][Full Text] [Related]
5. Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice.
Liu Y; Xie Q; Ma Y; Lin C; Li J; Hu B; Liu C; Zhao Y
Int J Pharm; 2022 Dec; 629():122352. PubMed ID: 36374798
[TBL] [Abstract][Full Text] [Related]
6. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y
Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615
[TBL] [Abstract][Full Text] [Related]
7. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.
Liu H; Han J; Lv Y; Zhao Z; Zheng S; Sun Y; Sun T
J Nanobiotechnology; 2023 Jul; 21(1):208. PubMed ID: 37408047
[TBL] [Abstract][Full Text] [Related]
8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
9. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
[TBL] [Abstract][Full Text] [Related]
10. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
11. Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles.
Zhao M; Yang X; Fu H; Chen C; Zhang Y; Wu Z; Duan Y; Sun Y
ACS Appl Mater Interfaces; 2021 Jul; 13(28):32763-32779. PubMed ID: 34235912
[TBL] [Abstract][Full Text] [Related]
12. RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC.
Chen Y; Shang H; Wang C; Zeng J; Zhang S; Wu B; Cheng W
Int J Nanomedicine; 2022; 17():105-123. PubMed ID: 35027829
[TBL] [Abstract][Full Text] [Related]
13. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
14. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
Ma Y; Han J; Jiang J; Zheng Z; Tan Y; Liu C; Zhao Y
Life Sci; 2020 Dec; 262():118565. PubMed ID: 33038371
[TBL] [Abstract][Full Text] [Related]
16. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer.
Nesbitt H; Logan K; Thomas K; Callan B; Gao J; McKaig T; Taylor M; Love M; Stride E; McHale AP; Callan JF
Cancer Lett; 2021 Oct; 517():88-95. PubMed ID: 34119606
[TBL] [Abstract][Full Text] [Related]
17. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
18. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody.
Li Z; Cai H; Li Z; Ren L; Ma X; Zhu H; Gong Q; Zhang H; Gu Z; Luo K
Bioact Mater; 2023 Mar; 21():299-312. PubMed ID: 36157245
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
20. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
